{"product_id":"tyvyt-sintilimab","title":"TYVYT  (Sintilimab)","description":"\u003cp\u003eTYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) is a fully human IgG4 monoclonal antibody, which specifically binds to PD-1 expressed on the surface of T cells to block the interaction between PD-L1 and PD-1, thereby reinvigorating exhausted T cell to gain effector function to kill tumor cells.\u003cbr\u003e\u003cbr\u003eIn December 2018, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was first approved by the China NMPA for the treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy.\u003c\/p\u003e\u003cp\u003eIn February 2021, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the China NMPA in combination with pemetrexed and platinum chemotherapy as first-line therapy for the treatment of nonsquamous non-small cell lung cancer.\u003c\/p\u003e\u003cp\u003eIn June 2021, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the China NMPA in combination with gemcitabine and platinum chemotherapy as the first-line therapy for the treatment of squamous non-small cell lung cancer.\u003c\/p\u003e\u003cp\u003eIn June 2021, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the China NMPA in combination with BYVASDA\u003csup\u003e®\u003c\/sup\u003e (bevacizumab biosimilar) as the first-line therapy for the treatment of Hepatocellular Carcinoma.\u003c\/p\u003e\u003cp\u003eIn December 2021, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was the only PD-1 inhibitor in China with four major indications (1L nsq NSCLC, 1L sq NSCLC, 1L HCC and cHL) approved and included in China’s NRDL.\u003c\/p\u003e\u003cp\u003eIn June 2022，TYVYT️\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the NMPA for the fifth indication in combination with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).\u003cbr\u003e\u003cbr\u003eIn June 2022, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the NMPA for the sixth indication in combination with fluorouracil and platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.\u003c\/p\u003e","brand":"Innovent Bio, China","offers":[{"title":"Default Title","offer_id":44797954097195,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0711.jpg?v=1787022217","url":"https:\/\/xomeds.com\/products\/tyvyt-sintilimab","provider":"XOMEDS","version":"1.0","type":"link"}